Prescribing Information
PATIENT SITE

DARZALEX FASPRO® DOSING & ADMINISTRATION GUIDE

DARZALEX® DOSING & ADMINISTRATION GUIDE

DARZALEX FASPRO^® monotherapy is the first and only FDA-approved treatment in high-risk smoldering multiple myeloma¹

INDICATIONS AND DOSING

Newly Diagnosed
- DVRd
- DRd
- DVMP
- DVTd
Relapsed or Refractory

NCCN RECOMMENDATIONS

PATIENT PROFILE

PROVEN EFFICACY

DEMONSTRATED SAFETY

PROVEN EFFICACY

DEMONSTRATED SAFETY

HIGH-RISK SUBGROUP

FRAILTY SUBGROUP

CONTINUING DRd TREATMENT

MAINTAINING TREATMENT BENEFITS

TIME TO DEEPEST RESPONSE

SAFETY OVER TIME

ADVANCING PATIENT CARE

PRACTICE SUPPORT

PATIENT SUPPORT

MECHANISM OF ACTION

FOR APPs & NURSES

PRESCRIBING INFORMATION
Important Safety Information
- DARZALEX FASPRO^® Important Safety Information
- DARZALEX^® Important Safety Information
Contact Us
Dosing & Administration Guide
- DARZALEX FASPRO^® Dosing & Administration Guide
- DARZALEX^® Dosing & Administration Guide
PATIENT SITE
MM Portfolio
This site is intended for
US healthcare professionals.

NOW APPROVED

DARZALEX FASPRO^® + VRd is approved in transplant-ineligible patients with newly diagnosed multiple myelomaNDMM¹

Site Map

Home
Site Map

Product Use
Frontline DVRd
Frontline DRd
Continuing DRd treatment
Resources
For APPs and Nurses

Medical Information Center
Site Map